CELCUITY INC
Celcuity Inc (CELC) is a clinical-stage diagnostics company focused on precision oncology. The business works on identifying and validating biomarkers and developing assays that aim to help match cancer patients with targeted therapies or clinical trial options. Investors typically watch clinical data readouts, regulatory progress and any partnerships with pharmaceutical companies, as these milestones can influence future commercial potential. With a market capitalisation around $2.8 billion, Celcuity is relatively small and may exhibit significant share-price volatility. As with any early-stage healthcare company, risks include clinical setbacks, regulatory hurdles and funding needs. This summary is for educational purposes only and not personalised investment advice; values can rise or fall and past performance is not a guide to future results. Consider seeking independent financial or medical advice to assess suitability for your circumstances.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Celcuity's stock with a target price of $110.5, indicating growth potential.
Financial Health
Celcuity Inc. shows strong cash generation and a solid book value per share, indicating financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CELC
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Precision oncology focus
Works on biomarkers and assays to better match patients with therapies; scientific breakthroughs could drive upside, though clinical success is uncertain.
Partnership potential
Collaborations with pharma could accelerate development and commercialisation, but such deals typically depend on positive trial and regulatory outcomes.
Early-stage risks
Clinical, regulatory and funding risks can cause significant share-price swings; this profile may suit investors prepared for high volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.